Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 17/20 | 0.64 |
| ▸ | MAOA | P21397 | 1/20 | 0.64 |
| ▸ | GRM5 | P41594 | 6/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29758920 | 1.00 | MAOB (0.64) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL27916588 | 0.98 | MAOB (0.62) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL915230 | 0.89 | MAOB (0.51) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL15818326 | 0.86 | MAOB (0.59) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL769330 | 0.85 | FABP6 (0.58) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL15818861 | 0.82 | MAOB (0.58) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL1924055 | 0.81 | MAOB (0.54) | MAOBMAOAGRM5NPC1RAB9A | |
| SCHEMBL4728838 | 0.79 | MAOB (0.66) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL2961997 | 0.78 | MAOB (0.54) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL8578811 | 0.78 | MAOB (0.64) | MAOBMAOAGRM5NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112079826-B | Steroid synthetase inhibitor and treatment application thereof | 广州中医药大学(广州中医药研究院) | 2022-07-29 | — | — | CN | claimed |
| WO-2022057142-A1 | STEROID SYNTHETASE INHIBITORS AND THERAPEUTIC USE THEREOF | 广州中医药大学(广州中医药研究院) | 2022-03-24 | — | — | WO | claimed |
| CN-112079826-A | Steroid synthetase inhibitor and treatment application thereof | 广州中医药大学(广州中医药研究院) | 2020-12-15 | — | — | CN | claimed |
| US-12497377-B2 | Tricyclic spiro compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-12-16 | — | — | US | disclosed |
| WO-2025036382-A1 | SULFONAMIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海复宏汉霖生物医药有限公司 | 2025-02-20 | — | — | WO | disclosed |
| US-12157726-B2 | P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof | SHANGHAI ZHIMENG BIOPHARMA INC. | 2024-12-03 | — | — | US | disclosed |
| US-20240368109-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME LLC (US) | 2024-11-07 | — | — | US | disclosed |
| EP-4404935-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | Merck Sharp & Dohme LLC (US) | 2024-07-31 | — | — | EP | disclosed |
| WO-2024140431-A1 | COMPOUNDS COMPRISING HETEROARYL RINGS AND COMPOSITIONS AND METHODS THEREOF | IONGEN THERAPEUTICS CO., LTD. (CN) | 2024-07-04 | — | — | WO | disclosed |
| US-20240182436-A1 | SUBSTITUTED SULFONAMIDE-CHROMAN COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| WO-2024040267-A2 | DIRECT SYNTHESIS OF N-(3-SUBSTITUTED-CHROMAN-4-YL)-7H- PYRROLO[2,3-D]PYRIMIDIN-4-AMINES AND DERIVATIVES THEREOF | MITOKININ, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| US-6316437-B1 | ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO., INC. | 2001-11-13 | — | — | US | disclosed |
| WO-2001045704-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2001-06-28 | — | — | WO | disclosed |
| WO-1998009969-A1 | NOVEL ARYL-PYRIDAZINES | ASTRA PHARMACEUTICALS LTD. (GB) | 1998-03-12 | — | — | WO | disclosed |
| US-5521147-A | HERBICIDES | FMC CORPORATION (US) | 1996-05-28 | — | — | US | disclosed |
| US-4992564-A | Preparation of 6-substituted 4-chromanones | MALLINCKRODT, INC. (US) | 1991-02-12 | — | — | US | disclosed |
| EP-0400403-A2 | N-aryl-nitrogen-heterocycles | BAYER AG (DE) | 1990-12-05 | — | — | EP | disclosed |
| US-4918203-A | Preparation of 6-substituted 4-chromanones | MALLINCKRODT INC. | 1990-04-17 | — | — | US | disclosed |
| EP-0228172-B1 | PREPARATION OF 6-SUBSTITUTED 4-CHROMANONES | Mallinckrodt, Inc. (a Delaware corporation) (US) | 1990-03-07 | — | — | EP | disclosed |
| EP-0228172-A1 | Preparation of 6-substituted 4-chromanones | Mallinckrodt, Inc. (a Delaware corporation) (US) | 1987-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12157726-B2 | P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof | KCNJ2, KCNN2, KCNH2 | MAOB 1320/4885MAOA 1302/4885GRM5 1632/4885 |
| US-20240368109-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRNA5, CHRNA6 | MAOB 386/4885MAOA 294/4885GRM5 93/4885 |
| US-12497377-B2 | Tricyclic spiro compound | PTGER4, PTGER1, PTGER3 | MAOB 2126/4885MAOA 2145/4885GRM5 874/4885 |
| US-20240182436-A1 | SUBSTITUTED SULFONAMIDE-CHROMAN COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | ARSA, SNCA, F12 | MAOB 186/4885MAOA 267/4885GRM5 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.